Table 3.
Uni- and multivariate Cox’s analyses for overall survival.
| Factor | N of Data | N of event (%) | Level | Univariate HR (95% CI) |
p | Multivariate HR (95% CI) |
p |
|---|---|---|---|---|---|---|---|
| Age | 71 | 28 (39) | ≥ vs. <82 years old 1 | 0.75 (0.29, 1.97) | 0.57 | ||
| Sex | 71 | 28 (39) | Male vs. Female | 2.86 (1.01, 8.13) | 0.048 | 4.38 (1.02, 18.9) | 0.047 |
| Performance status | 71 | 28 (39) | ≥1 vs. 0 | 5.10 (1.81, 14.4) | 0.002 | 7.66 (1.57, 37.3) | 0.012 |
| Major underlying liver disease | 71 | 28 (39) | NAFLD vs. Others | 0.74 (0.28, 1.96) | 0.55 | ||
| Treatment history | 71 | 28 (39) | +(recurrence or IM) vs.−(primary tumor) | 2.91 (1.06, 7.98) | 0.038 | 5.44 (0.95, 31.1) | 0.057 |
| Longest tumor diameter | 71 | 28 (39) | ≥ vs. <32 mm 1 | 0.87 (0.34, 2.23) | 0.77 | ||
| Tumor volume | 71 | 28 (39) | ≥ vs. <25.6 cc 1 | 1.05 (0.40, 2.71) | 0.92 | ||
| Child–Pugh score | 71 | 28 (39) | A6, B7 vs. A5 | 3.27 (1.15, 9.31) | 0.026 | 2.02 (0.48, 8.42) | 0.34 |
| TNM (UICC8th) | 71 | 28 (39) | ≥T2 vs. T1 | 1.40 (0.42, 4.72) | 0.58 | ||
| Okuda staging | 71 | 28 (39) | II vs. I | 2.12 (0.52, 8.70) | 0.30 | ||
| BCLC staging | 71 | 28 (39) | B–D vs. 0, A | 1.56 (0.54, 4.53) | 0.41 | ||
| Liver damage | 71 | 28 (39) | B vs. A | 2.52 (0.92, 6.93) | 0.073 | ||
| HH15 | 71 | 28 (39) | >0.55 vs. ≤0.55 2 | 1.26 (0.41, 3.91) | 0.69 | ||
| LHL15 | 71 | 28 (39) | <0.92 vs. ≥0.92 2 | 1.62 (0.38, 6.88) | 0.51 | ||
| ICGR15 | 71 | 28 (39) | ≥10 vs. <10 % 2 | 1.71 (0.31, 9.50) | 0.54 | ||
| K-ICG | 71 | 28 (39) | <0.15 vs. ≥0.15, ≤0.22 % | 1.62 (0.38, 6.88) | 0.58 | ||
| ALBI grade | 71 | 28 (39) | 2, 3 vs. 1 | 1.53 (0.59, 4.00) | 0.38 | ||
| FIB-4 index | 71 | 28 (39) | ≥2.67 vs. <2.67 | 0.86 (0.18, 4.15) | 0.85 | ||
| Treatment options | 71 | 28 (39) | Inoperable vs. operable | 6.90 (2.05, 23.3) | 0.002 | 2.03 (0.43, 9.59) | 0.37 |
| 71 | 28 (39) | RFA untreatable vs. treatable | 0.89 (0.25, 3.16) | 0.86 | |||
| 71 | 28 (39) | TACE untreatable vs. treatable | 2.24 (0.83, 6.07) | 0.11 | |||
| Dose fractionation | 71 | 28 (39) | 72.6 GyRBE/22 Fr vs. 66 GyRBE/10 Fr | 1.49 (0.55, 4.06) | 0.43 | ||
| Vicinity to the gastrointestinal tract | 71 | 28 (39) | ≤ vs. >1 cm | 1.28 (0.47, 3.52) | 0.63 | ||
| Alpha fetoprotein | 71 | 28 (39) | >20 vs. ≤20 ng/mL 2 | 3.36 (1.22, 9.22) | 0.019 | 2.05 (0.43, 9.73) | 0.37 |
| PIVKA-II | 71 | 28 (39) | >40 vs. ≤40 mAU/mL 2 | 2.88 (1.04, 7.94) | 0.042 | 3.55 (0.81, 15.5) | 0.092 |
| Local control | 71 | 28 (39) | Failure vs. control | 3.64 (0.83. 16.0) | 0.09 |
1 Cut-off value was the median value; 2 cut-off value was the upper limit of normal reference levels; HR = hazard ratio.